Efficacy of preoperative inhaled LAMA/LABA combinations in patients with lung cancer and untreated COPD

被引:0
|
作者
Mizuno, Yoshimasa [1 ]
Shirahashi, Koyo [2 ]
Yamamoto, Hirotaka [2 ]
Matsumoto, Mitsuyoshi [2 ]
Miyamoto, Yusaku [2 ]
Komuro, Hiroyasu [2 ]
Hagiwara, Kiyohiko [2 ]
Doi, Kiyoshi [2 ]
Iwata, Hisashi [3 ]
机构
[1] Chuno Kosei Hosp, Dept Gen Thorac Surg, Wakakusa Dori 5-1, Seki 5013802, Japan
[2] Univ Gifu, Grad Sch Med, Dept Gen & Cardiothorac Surg, Gifu, Japan
[3] Univ Hosp Gifu, Ctr Resp Dis, Dept Gen Thorac Surg, Gifu, Japan
来源
MINERVA SURGERY | 2021年 / 76卷 / 06期
关键词
Lung neoplasms; Thoracic surgery; Pulmonary disease; chronic obstructive; Bronchodilator agents; Drug combinations; OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY COMPLICATIONS; TIOTROPIUM; RESECTION; SURGERY; TRENDS; IMPACT;
D O I
10.23736/S2724-5691.21.08717-79
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with a high incidence of postoperative pulmonary complications (PPCs). When untreated COPD is found before lung cancer surgery, we have been actively intervening therapeutically with inhaled long-acting muscarinic antagonist (LAMA)/long-acting beta 2-agonist (LABA) combinations. We investigated the efficacy of preoperative LAMA/LABA treatment. METHODS: We reviewed data from 261 patients who underwent pulmonary resection for primary lung cancer. Of these, 59 patients showed unrecognized obstructive ventilatory impairment on respiratory function testing. We administered inhaled drugs for 38 patients, of whom 22 patients treated with LAMA/LABA combinations and diagnosed with COPD were retrospectively analyzed regarding improvement of respiratory function and postoperative course. RESULTS: Median duration of LAMA/LABA treatment was 19.5 days (interquartile range (IQR), 10.5-28.3 days). Percentage predicted vital capacity (%VC) (pretreatment: 95.6%, IQR 91.9-111.7 vs. posttreatment 102.8%, IQR 92.3113.0), forced expiratory volume in 1 s (FEV1) (1.76 L, 1.43-2.12 vs. 2.00 L, 1.78-2.40), forced VC (FVC) (2.96 L, 2.64-3.47 vs. 3.22 L, 2.95-3.74) and percentage predicted FEV1 (80.1%, 68.4-97.0 vs. 91.6%, 80.3-101.9) were all significantly improved (P 0.05 each). FEV1/FVC tended to be improved, but not significantly. No significant difference in improvement of respiratory function was seen between short-term (<= 2 weeks) and normal-term ( 2 weeks) treatment. PPCs occurred in 4 of 22 patients (18.2%), showing no significant difference compared to patients with COPD previously treated with inhaled drugs (2/20; 10.0%). CONCLUSIONS: Respiratory function is improved by preoperative LAMA/LABA treatment even in the short term. Starting treatment allows even COPD patients diagnosed on preoperative screening to experience the same frequency of PPCs as previously treated patients.
引用
收藏
页码:592 / 597
页数:6
相关论文
共 50 条
  • [1] Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD
    Kobayashi, Seiichi
    Suzuki, Satoshi
    Niikawa, Hiromichi
    Sugawara, Takafumi
    Yanai, Masaru
    RESPIROLOGY, 2009, 14 (05) : 675 - 679
  • [2] Clinical synergism of LABA/LAMA combinations in COPD patients
    Rogliani, Paola
    Calzetta, Luigino
    Ora, Josuel
    Puxeddu, Ermanno
    Cazzola, Mario
    Matera, Maria Gabriella
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [3] LABA/LAMA combinations efficacy evaluation therapy of COPD patients with emphasized morning and night symptoms
    Pavlovic, Tanja
    Pavlovic, Dejan
    Vukcevic, Miodrag
    Zugic, Vladimir
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [4] Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
    Aziz, Mohamed Ismail Abdul
    Tan, Ling Eng
    Wu, David Bin-Chia
    Pearce, Fiona
    Chua, Gerald Seng Wee
    Lin, Liang
    Tan, Ping-Tee
    Ng, Kwong
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 : 3203 - 3231
  • [5] Efficacy of Double Bronchodilation (LABA plus LAMA) in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer
    Leiro-Fernandez, Virginia
    Priegue Carrera, Ana
    Fernandez-Villar, Alberto
    ARCHIVOS DE BRONCONEUMOLOGIA, 2016, 52 (12): : 622 - 623
  • [6] LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
    Rogliani, Paola
    Calzetta, Luigino
    Braido, Fulvio
    Cazzola, Mario
    Clini, Enrico
    Pelaia, Girolamo
    Rossi, Andrea
    Scichilone, Nicola
    Di Marco, Fabiano
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 : 3115 - 3130
  • [7] LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
    Rodrigo, Gustavo J.
    Price, David
    Anzueto, Antonio
    Singh, Dave
    Altman, Pablo
    Bader, Giovanni
    Patalano, Francesco
    Fogel, Robert
    Kostikas, Konstantinos
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 12 : 907 - 922
  • [8] Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD
    Banerji, Donald
    Mahler, Donald A.
    Hanania, Nicola A.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (07) : 767 - 780
  • [9] Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
    Anthony D’Urzo
    Kenneth R. Chapman
    James F. Donohue
    Peter Kardos
    M. Reza Maleki-Yazdi
    David Price
    Pulmonary Therapy, 2019, 5 : 23 - 41
  • [10] Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
    D'Urzo, Anthony
    Chapman, Kenneth R.
    Donohue, James F.
    Kardos, Peter
    Maleki-Yazdi, M. Reza
    Price, David
    PULMONARY THERAPY, 2019, 5 (01) : 23 - 41